| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
Drugs for disorders of the central nervous system (CNS) form the second-ranked
therapeutic area in terms of global pharmaceutical sales, reaching total
retail sales in 2006 of $73.4 billion-equivalent to 19% of total
pharmaceutical sales. However, pharmaceutical companies are subject to intense
pressure from payers to moderate their prices. Additionally, physicians and
patients face ever-more-daunting reimbursement barriers. Our analysis of the
fi ve-year pricing trend for 40 best-selling CNS therapies (20 neurology drugs
and 20 psychiatric agents) shows that prices generally rise steadily in the
United States but typically remain stable or decline in other major markets.
Get the Answers You Need to Shape Your Strategy
- From 2003 to 2007, the U.S. prices of a sample of 20 best-selling
neurology drugs increased by an average of 44%. Which other major market saw
an increase in average prices for neurology drugs over this period? How did
prices in this therapeutic area evolve in other markets?
- From 2003 to 2007, the U.S. prices of a sample of 20 leading psychiatric
drugs increased by an average of33%. What were the pricing trends for
psychiatric drugs in other markets over this period? How did the expiration of
patents on several blockbuster agents affect overall pricing trends for
psychiatric drugs?
- Leading pharmacy benefi t management companies (PBMs) in the United States
report very varied spending trends for best-selling CNS drug classes in 2007.
Which drug classes experienced strong growth in utilization and average
prescription costs? Which drug classes underwent a decline in average
prescription costs?
- The U.K. government has recently announced plans to reform its
pharmaceutical pricing system and to implement a new constitution for the
National Health Service. How will the reforms affect drug prices in the United
Kingdom? What will the government do to promote pharmaceutical innovation?
Scope
- Geographic pricing trends: price evolution from 2003 to 2007 of 20
best-selling neurology drugs and 20 leading psychiatric agents in the United
States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
- Drug class pricing trends: price evolution from 2003 to 2007 of leading
antiepileptic drugs, antidementia drugs, Parkinson's disease therapies,
triptans, multiple sclerosis therapies, antidepressants, antipsychotics, and
treatments for attention-defi cit/hyperactivity disorder.
- Reimbursement trends in major markets: leading PBMs' CNS drug benefi t
trends in the United States; promoting increased use of generics in France;
prescribing quotas for certain drug classes in Germany; new pharmaceutical
budget in Italy; amendments to the Spanish reference pricing system; price
cuts in the United Kingdom; latest biennial price revisions in Japan.
- Outlook and implications for the pharmaceutical industry: contrasting
pricing trends in the United States and other major markets; lower price
sensitivity in the biologics and neurology markets; impact of blockbuster
patent expiration and generics competition; rebate trends in the United
States; use of reference pricing in Europe; price cuts in some major markets.
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Geographic Pricing Trends
- Methodology
- United States
- France
- Germany
- Italy
- Spain
- United Kingdom
- Europe
- Japan
- International Trends
- Drug Class Pricing Trends
- Antiepileptic Drugs
- Anti-Dementia Drugs
- Parkinson's Disease Therapies
- Triptans
- Multiple Sclerosis Therapies
- Antidepressants
- Antipsychotics
- Treatments for Attention-Defi cit/Hyperactivity Disorder
- Reimbursement Trends
- United States
- Continued Criticism of Drug Prices
- Leading PBMs' CNS Drug Benefi t Trends
- Utilization Management Tools in Depression
- Wal-Mart Offers Low-Priced Generics
- France
- New Patient Charges for Prescription Drugs
- Expansion of the Reference Pricing System
- Promoting Increased Use of Generic Drugs
- Germany
- Rebate Contracts
- Prescribing Quotas for Certain Drug Classes
- Undertreatment of Common Disorders
- Italy
- New Pharmaceutical Budget
- Spain
- Court Ruling Strengthens Intellectual Property Protection
- Increasing Barriers to Parallel Trade
- Amendments to the Reference Pricing System
- Restrictions on Generics Substitution
- United Kingdom
- Price Cuts Agreed in Negotiations for New Drug Pricing System
- Parliamentary Review of NICE
- Restrictions on Reimbursement of Dementia Therapies
- Japan
- Latest Biennial Price Revisions
- Outlook and Implications for the Pharmaceutical Industry
Tables
- 1. Drugs Covered in This Report
- 2. Average Annual Exchange Rates Against the U.S. Dollar, 2003-2007
- 3. U.S. Prices of Leading Neurology Drugs as a Percentage of Average
Prices in Japan and the Five Leading European Markets, 2003-2007
- 4. Price Evolution of Leading Neurology Drugs in the United States,
2003-2007
- 5. U.S. Prices of Leading Psychiatric Drugs as a Percentage of Average
Prices in Japan and the Five Leading European Markets, 2003-2007
- 6. Price Evolution of Leading Psychiatric Drugs in the United States,
2003-2007
- 7. French Prices of Leading Neurology Drugs as a Percentage of U.S.
Prices, 2003-2007
- 8. Price Evolution of Leading Neurology Drugs in France, 2003-2007
- 9. French Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 10. Price Evolution of Leading Psychiatric Drugs in France, 2003-2007
- 11. German Prices of Leading Neurology Drugs as a Percentage of U.S.
Prices, 2003-2007
- 12. Price Evolution of Leading Neurology Drugs in Germany, 2003-2007
- 13. German Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 14. Price Evolution of Leading Psychiatric Drugs in Germany, 2003-2007
- 15. Italian Prices of Leading Neurology Drugs as a Percentage of U.S.
Prices, 2003-2007
- 16. Price Evolution of Leading Neurology Drugs in Italy, 2003-2007
- 17. Italian Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 18. Price Evolution of Leading Psychiatric Drugs in Italy, 2003-2007
- 19. Spanish Prices of Leading Neurology Drugs as a Percentage of U.S.
Prices, 2003-2007
- 20. Price Evolution of Leading Neurology Drugs in Spain, 2003-2007
- 21. Spanish Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 22. Price Evolution of Leading Psychiatric Drugs in Spain, 2003-2007
- 23. U.K. Prices of Leading Neurology Drugs as a Percentage of U.S. Prices,
2003-2007
- 24. Price Evolution of Leading Neurology Drugs in the United Kingdom,
2003-2007
- 25. U.K. Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 26. Price Evolution of Leading Psychiatric Drugs in the United Kingdom,
2003-2007
- 27. European Average Prices of Leading Neurology Drugs as a Percentage of
U.S. Prices, 2003-2007
- 28. Evolution of European Average Prices of Leading Neurology Drugs,
2003-2007
- 29. European Average Prices of Leading Psychiatric Drugs as a Percentage
of U.S. Prices, 2003-2007
- 30. Evolution of European Average Prices of Leading Psychiatric Drugs,
2003-2007
- 31. Japanese Prices of Leading Neurology Drugs as a Percentage of U.S.
Prices, 2003-2007
- 32. Price Evolution of Leading Neurology Drugs in Japan, 2003-2007
- 33. Japanese Prices of Leading Psychiatric Drugs as a Percentage of U.S.
Prices, 2003-2007
- 34. Price Evolution of Leading Psychiatric Drugs in Japan, 2003-2007
- 35. Select Drugs Excluded From Generics Substitution in Spain
Figures
- 1. Average Prices of Neurology Drugs in Europe and Japan as a Percentage
of U.S. Prices, 2003-2007
- 2. Pricing Trends for Neurology Drugs in Major Markets, 2003-2007
- 3. Average Prices of Psychiatric Drugs in Europe and Japan as a Percentage
of U.S. Prices, 2003-2007
- 4. Pricing Trends for Psychiatric Drugs in Major Markets, 2003-2007
- 5. Average Prices of Antiepileptic Drugs in Europe as a Percentage of U.S.
Prices, 2003-2007
- 6. Pricing Trends for Antiepileptic Drugs in the United States and Europe,
2003-2007
- 7. Average Prices of Anti-Dementia Drugs in Europe as a Percentage of U.S.
Prices, 2003-2007
- 8. Pricing Trends for Anti-Dementia Drugs in the United States and Europe,
2003-2007
- 9. Average Prices of Parkinson's Disease Therapies in Europe as a
Percentage of U.S. Prices, 2003-2007
- 10. Pricing Trends for Parkinson's Disease Therapies Drugs in the United
States and Europe, 2003-2007
- 11. Average Prices of Triptans in Europe as a Percentage of U.S. Prices,
2003-2007
- 12. Pricing Trends for Triptans in the United States and Europe, 2003-2007
- 13. Average Prices of Multiple Sclerosis Therapies in Europe as a
Percentage of U.S. Prices, 2003-2007
- 14. Pricing Trends for Multiple Sclerosis Therapies in the United States
and Europe, 2003-2007
- 15. Average Prices of Antidepressants in Europe as a Percentage of U.S.
Prices, 2003-2007
- 16. Pricing Trends for Antidepressants in the United States and Europe,
2003-2007
- 17. Average Prices of Antipsychotics in Europe as a Percentage of U.S.
Prices, 2003-2007
- 18. Pricing Trends for Antipsychotics in the United States and Europe,
2003-2007
- 19. Average Prices of Attention-Defi cit/Hyperactivity Disorder Treatments
in Europe as a Percentage of U.S. Prices, 2003-2007
- 20. Pricing Trends for Attention-Defi cit/Hyperactivity Disorder
Treatments in the United States and Europe, 2003-2007
- 21. Generics Penetration Rates in France for Select CNS Compounds, June
2007
|
